ArticleGland surgery2026
Safety and efficacy of radiofrequency ablation of benign thyroid nodules in patients with a history of implantable cardioverter defibrillators (ICDs), permanent pacemakers (PPMs), and implantable cardiac monitors (ICMs).
Article in Gland surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Radiofrequency ablation (RFA) has emerged as an effective, minimally invasive treatment option for benign thyroid nodules. However, safety in patients with cardiac implantable electronic devices (CIEDs) such as implantable cardioverter defibrillators (ICDs), permanent pacemakers (PPMs), and implantable cardiac monitors (ICMs) is unclear, given theoretical risks of electromagnetic interference (EMI). As the use of both RFA and CIEDs continues to increase, establishing evidence-based safety guidance for this population is essential. This study aimed to evaluate the safety of RFA for benign thyroid nodules in patients with CIEDs. Methods: This retrospective study included 7 patients with a history of ICDs, ICMs, or PPMs and benign thyroid nodules who underwent RFA. All CIEDs were interrogated both before and after the procedure. A magnet was placed over ICDs, and electrocardiogram (ECG) monitoring was performed to detect arrhythmias or mode switching. Outcomes included the incidence of post-RFA complications, including possible cardiac implant malfunctions and volume reduction rate (VRR) at 6 months. Results: The mean age of the patients was 72.1±12.5 years, with 71.4% of the patients being female. The mean VRR at 6 months was 73.8%±24.9%. No peri-procedural complications occurred, and no patient demonstrated clinically significant EMI, inappropriate sensing or pacing, arrhythmias, device resets, or structural lead damage. All patients tolerated the procedure without adverse events. Conclusions: RFA appears to be a safe and effective treatment for benign thyroid nodules in patients with a history of ICDs, ICMs, and PPMs. Our experience demonstrated the safety of RFA and supported its utility in this high-risk population when performing these procedures with appropriate monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.